Evidence map›Paper›PMID 42327358›Full record

ArticleData in brief2026

SiNuS: A comprehensive dataset for singular nuclei segmentation for

Md Shakhawat Hossain, Md Sahilur Rahman, Munim Ahmed

Abstract read
In one paragraph

Article in Data in brief, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Md Shakhawat HossainSchool of Informatics, Kochi University of Technology, Kami, Kochi, 782-8502, Japan.
Md Sahilur RahmanRIoT Center, Independent University, Bangladesh, Dhaka, 1245, Bangladesh.
Munim AhmedRIoT Center, Independent University, Bangladesh, Dhaka, 1245, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Singular nuclei are those that are intact and do not overlap with neighboring nuclei. According to the American Society of Clinical Oncology and the College of American Pathologists ASCO/CAP, the human epidermal growth factor receptor 2 (HER2) grading of cancer must be performed using only singular nuclei from in situ hybridization (ISH) images, regardless of cancer type. Therefore, accurate segmentation of singular nuclei is critical for automated HER2 grading in digital pathology, performed routinely for breast cancer patients. A few methods have been proposed for singular nuclei segmentation but they rely on private datasets. Although numerous public nuclei datasets are available, but they are not suitable for singular nuclei detection. We developed a comprehensive public dataset for singular nuclei segmentation. The dataset includes original annotations on Dual-ISH 20× images, binary masks, multicolor masks and nuclei-boundary masks to support diverse analysis. The annotation was done independently by three expert pathologists to ensure clinical relevance and minimize biases. Then, we included both the inclusive and exclusive nuclei selection representing combined annotation from any expert and strong consensus annotation among all experts, respectively. The dataset consists of 39 image patches comprising 1856 inclusive and 1284 exclusive singular nuclei, extracted from 10 HER2-negative and 11 HER2-positive breast cancer patients. The dataset was validated through experiments using deep learning-based segmentation models. Therefore, this dataset is a clinically relevant and first publicly available resource for the development and evaluation of automated singular nuclei segmentation and HER2 grading methods in digital pathology.

Indexed as

Breast cancerComputational pathologyHER2 gradingHistopathological image analysisNuclei segmentation

Identifiers

PMID42327358
PMCPMC13277659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.